Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Ribo Life IPO: SiRNA Story Good, Issue Seems Slightly Overpriced Considering the Long Waiting Game

Equity Bottom-Up

Suzhou Ribo Life Science / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/suzhou-ribo-life-science-co-ltd" target="_blank" data-smartkarma-citation="entities:45112:1" rel="noopener">Suzhou Ribo Life Science (SRL HK)</a> entered into a licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).</li>
<li>Ribo Life will receive an upfront payment of US$60M and cumulative payments could reach US$4.4B if certain development, regulatory and commercial milestones are achieved, plus potential royalties on net sales.</li>
<li>The deal has the potential to bear fruits for Ribo Life only in the long term. At the current share price, the stock does feel overvalued to an extent.</li>
</ul>



Suzhou Ribo Life Science (SRL HK) entered into a licensing agreement with Madrigal Pharmaceuticals for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Ribo Life will receive an upfront payment of US$60M and cumulative payments could reach US$4.4B if certain development, regulatory and commercial milestones are achieved, plus potential royalties on net sales.
The deal has the potential to bear fruits for Ribo Life only in the long term. At the current share price, the stock does feel overvalued to an extent.


Ribo Life Science (6938 HK): Madrigal MASH Deal A Positive, But Still a Long Waiting Game